Vendor Intelligence Report: Shandong Shengyuan Peptide Technology

Published 13 Jun 2026. 20-page investigative report on who is behind Shandong Shengyuan Peptide Technology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 28 Finnrick lab tests, Shengyuan is 22 pass / 6 fail, for a 79% overall pass rate. The record is mixed rather than disqualifying: Tirzepatide is the stronger tracked line, while Retatrutide carries the weaker product-specific signal and needs current-lot verification if a buyer insists on this vendor.

That product signal sits beside a credibility problem. Shengyuan presents 2005 continuity and 18+ years of experience, but domain, certificate, product-page, archive, and social-timing records compress the export-facing operation into a recent 2025 launch. The site is also part of a young shared-hosting peptide storefront cluster built on the same Chinese B2B CMS pattern, raising recourse and continuity concerns rather than proving a single controller.

The identity trail is unresolved. A facility photo shows a related-but-not-identical Chinese/English entity name, the contact channel is a Gmail address, and mainland registry confirmation could not be obtained from the investigation node. Captured product pages show GLP-1 catalog depth and pricing, but no visible batch COA/HPLC files; the same catalog overlaps compounds named in a CBP peptide-seizure context, adding shipment-loss exposure for U.S. buyers.

The public reputation record is thin, not loudly promotional: Finnrick found no promoter codes or coupon-style affiliate network in the swept X/web/Reddit/coupon channels, but also no credible buyer-review or import-record trail. Shengyuan may be a defensible small-test source for Tirzepatide only with batch verification; Retatrutide orders require a cleaner record or independent testing.

Inside the full report:

  • Appendix A Finnrick laboratory data, with per-product pass/fail rates and methodology-divergence charts for Tirzepatide and Retatrutide
  • RDAP, crt.sh, Wayback and product-date timeline assessing the 2005 / 18+ years history claim
  • Reverse-IP and FuwuCMS analysis of the shared peptide storefront cluster
  • Facility-photo entity-name comparison, Gmail-channel review and Chinese registry dead ends
  • Catalog, missing COA/HPLC review and CBP GLP-1 seizure-context mapping
  • Reputation and affiliate-promotion sweeps covering X, web coupons, Reddit web search, TradeWheel and Instagram signals

Risk assessment

  • Fabricated-history risk — high: The site claims 2005-2025 continuity and 18+ years, while RDAP and crt.sh place the domain and first certificate on 2025-08-20.
  • Shared-infrastructure / template-farm risk — high: Shengyuan is co-hosted on 47.254.90.56 with multiple new peptide storefronts using the same FuwuCMS pattern, raising continuity and recourse concerns.
  • Entity-verification and brand-authenticity risk — medium: The facility photo, English trading name, Gmail contact, and unverified registry trail do not give buyers a single registry-confirmed legal counterparty or authenticated channel list.
  • Product-specific quality-consistency risk — medium: Retatrutide is weaker (10 tests, 7 pass / 3 fail, 75.25%); Tirzepatide is stronger but not zero-fail (18 tests, 15 pass / 3 fail, 81.93%).
  • Regulatory and catalog-compliance risk — medium: Catalog GLP-1/peptide lines include Tirzepatide, Semaglutide, Retatrutide, Cagrilintide and Semax, all within the CBP peptide-seizure context; the site also lists a Sterodis category.
  • Independent reputation deficit risk — medium: No credible buyer reviews, Reddit/forum mentions, affiliate posts, coupon pages, import records, or confirmed LinkedIn company page were found in the supplied sweeps.